NCT05884242已完成1 期
Intervention Specific Appendix to PLATFORMPBNAP1001: Evaluation of The Effect of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Change From Baseline in C-reactive Protein (CRP)
研究概览
简要总结
The purpose of the study is to characterize the inflammatory response to lipopolysaccharide (LPS; molecules that contains fats and carbohydrates) in the presence of a targeted immune pathway modulator.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •A female participant must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of 5 months after adalimumab administration
- •A female participant must agree not to be pregnant or planning to become pregnant while enrolled in this study or within 5 months after the last dose of adalimumab
- •Must agree not to receive any vaccinations (including those authorized for emergency use, for example, Coronavirus disease-19 (COVID-19) within 2 weeks after study intervention administration
- •A male participant must agree not to plan to father a child while enrolled in this study or within 90 days after the last dose of study intervention
- •Has a negative severe acute respiratory syndrome coronavirus 2 (COVID-19) reverse transcription-polymerase chain reaction test within 72 hours prior to adalimumab administration on Day 1
- •Otherwise healthy on the basis of physical examination, medical history, and vital signs, and 12-lead electrocardiogram (ECG) performed at screening. Any abnormalities must be considered not clinically significant or consistent with the underlying illness in the study population, as specified in the applicable intervention specific appendix (ISA), and this determination must be recorded in the participant's source documents and initiated by the investigator
- •Otherwise healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel, blood coagulation, hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initiated by the investigator
排除标准
- •Has a history of congestive heart failure or chronic obstructive pulmonary disease
- •Has a history of central or peripheral nervous system demyelinating disease (for example, multiple sclerosis, optic neuritis, or including Guillain-Barre syndrome, respectively)
- •Has surgery planned within 10 weeks after the study intervention administration
- •Known allergies, hypersensitivity, or intolerance to adalimumab or its excipients
- •Had major illness or surgery, (for example, requiring general anesthesia) within 24 weeks before screening, or will not have fully recovered from illness or surgery, or has surgery planned during the time the participant is expected to participate in the study and up to 10 weeks after administration of the study intervention
- •History of liver or renal insufficiency significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances, unless consistent with the underlying disease of interest in the study population, if applicable
- •History of any type of immunodeficiency or autoimmune disease or disease treatment associated with immune suppression or lymphopenia, unless consistent with the underlying disease of interest in the study population, if applicable. These include but are not limited to bone marrow or organ transplantation, lymphoproliferative disorders, T- or B-cell deficiency syndromes, splenectomy, functional asplenia and chronic granulomatous disease
- •Has an active, acute, or chronic infection
研究组 & 干预措施
Active Arm: Adalimumab + Lipopolysaccharide (LPS) Challenge
Experimental
Healthy participants will receive adalimumab subcutaneous (SC) injections via prefilled syringe or prefilled pen on Day 1, followed by the LPS intravenous (IV) injection challenge on Day 6.
干预措施: Adalimumab (Drug)
Active Arm: Adalimumab + Lipopolysaccharide (LPS) Challenge
Experimental
Healthy participants will receive adalimumab subcutaneous (SC) injections via prefilled syringe or prefilled pen on Day 1, followed by the LPS intravenous (IV) injection challenge on Day 6.
干预措施: Lipopolysaccharide (LPS) (Drug)
Control Arm: LPS Challenge
Experimental
Participants will receive LPS IV injection on Day 6. No study interaction will be administered.
干预措施: Lipopolysaccharide (LPS) (Drug)
结局指标
主要结局
Change From Baseline in C-reactive Protein (CRP)
时间窗: From baseline up to Day 14
Change from the baseline in CRP levels will be reported.
次要结局
- Change From Baseline Tumour Necrosis Factor-alpha (TNF-alpha)(From baseline up to Day 14)
- Longitudinal Change From Baseline in Heart Rate(From baseline up to Day 14)
- Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs)(Up to Day 21 (end of study))
- Longitudinal Change From Baseline in Temperature(From baseline up to Day 14)
- Longitudinal Change From Baseline in Blood Pressure(From baseline up to Day 14)
- Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)(Up to Day 21 (end of study))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Endotoxin-induced Inflammatory and Behavioral Responses and Predictors of Individual DifferencesSickness BehaviorNCT02529592Karolinska Institutet22
已完成
不适用
Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell TransplantationHematologic DiseasesStem Cell TransplantationNCT03918343Centre Hospitalier Universitaire de Besancon95
已完成
不适用
Development of Novel Non-invasive Inflammometry Following Lipopolysaccharide, Endotoxin (LPS) Challenge in Healthy VolunteersHealthyNCT03044327Fraunhofer-Institute of Toxicology and Experimental Medicine11
撤回
4 期
Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic PatientsAscitesInfectionsCirrhosisNCT00760032Florencia Vargas-Vorackova
已完成
不适用
Biochemical effects of lipopolysaccharide (LPS) adsorber treatment during cardiac surgery using cardio-pulmonary bypassISRCTN50922450Papworth Hospital NHS Foundation Trust (UK)16